Financhill
Back

Editas Medicine Quote, Financials, Valuation and Earnings

Editas Medicine Price Quote

$2.67
-0.10 (-3.61%)
(Updated: November 15, 2024 at 5:55 PM ET)

Editas Medicine Key Stats

Sell
43
Editas Medicine (EDIT) is a Sell

Day range:
$2.76 - $2.98
52-week range:
$2.70 - $11.69
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
3.68
P/B ratio:
1.3%

Volume:
1.7M
Avg. volume:
2.1M
1-year change:
-67.49%
Market cap:
$228.7M
Revenue:
$78.1M
EPS:
$-2.56

How Much Does Editas Medicine Make?

Is Editas Medicine Growing As A Company?

  • What Is Editas Medicine's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.99%
  • What Is Editas Medicine's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Editas Medicine Stock Price Performance

  • Did Editas Medicine Stock Go Up Last Month?
    Editas Medicine share price went down by -14.51% last month
  • Did EDIT's Share Price Rise Over The Last Year?
    EDIT share price fell by -67.49% over the past 1 year

What Is Editas Medicine 52-Week High & Low?

Editas Medicine Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Editas Medicine?

  • How Much Debt Does Editas Medicine Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Editas Medicine Have?
    Cash and short term investments quarterly total is $265.1M
  • What Is Editas Medicine’s Book Value Per Share?
    Book value per share is 2.13

Is Editas Medicine Cash Flow Positive?

  • What Is EDIT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$181.8M
  • What Is Editas Medicine’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $1M
  • What Is Editas Medicine’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $194M

Editas Medicine Return On Invested Capital

  • Is Management Doing A Good Job?
    EDIT return on invested capital is -74.59%
  • What Is Editas Medicine Return On Assets?
    ROA measures how assets are converting to revenues and is -48.82%
  • What Is EDIT Return On Equity?
    ROE is a measure of profitability and is -74.59%

Editas Medicine Earnings Date & Stock Price

Editas Medicine Competitors

  • Who Are Editas Medicine's Competitors?
    Below is a list of companies who compete with Editas Medicine or are related in some way:
    • Adverum Biotechnologies Inc (ADVM)
    • Apellis Pharmaceuticals Inc (APLS)
    • EyePoint Pharmaceuticals Inc (EYPT)
    • Regenxbio Inc (RGNX)
    • Cassava Sciences Inc (SAVA)

Editas Medicine Dividend Yield

Editas Medicine Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 2.53%
Revenue: -98.86% -98.43%

Analyst Recommendations

Buy Recommendations: 10
Hold Recommendations: 9
Sell Recommendations: 0
Price Target: 9.07
Upside from Last Price: 227.49%

Major Shareholders

  • How many EDIT shares are owned by institutional investors?
    86.1M EDIT shares are owned by institutional investors
  • How many EDIT shares are owned by insiders?
    3M EDIT shares are owned by insiders